Liberum Capital Maintains “Buy” Rating for Non-standard Finance Plc (LON:NSF) stock. What’s the Best Move for Investors?

Non-Standard Finance plc (LON:NSF) Logo

Non-standard Finance Plc (LON:NSF) Rating Reaffirmed

Non-standard Finance Plc (LON:NSF) has had their stock rating reconfirmed as a solid “Buy” by professional analysts at Liberum Capital. This was revealed to investors in analysts note on Friday, 30 November.

Non-Standard Finance plc (LON:NSF) Ratings Coverage

Among 2 analysts covering Non-standard Finance Plc (LON:NSF), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Non-standard Finance Plc had 5 analyst reports since June 18, 2018 according to SRatingsIntel. On Friday, November 30 the stock rating was maintained by Liberum Capital with “Buy”. The rating was maintained by Peel Hunt with “Hold” on Thursday, August 2. Peel Hunt maintained the shares of NSF in report on Monday, June 18 with “Hold” rating. As per Friday, November 30, the company rating was maintained by Peel Hunt. The firm has “Buy” rating by Liberum Capital given on Thursday, November 22.

The stock increased 1.52% or GBX 1 during the last trading session, reaching GBX 67. About 589,406 shares traded or 209.21% up from the average. Non-Standard Finance plc (LON:NSF) has 0.00% since December 2, 2017 and is . It has underperformed by 15.62% the S&P500.

Non-Standard Finance plc engages in the consumer credit business in the United Kingdom. The company has market cap of 209.07 million GBP. It provides unsecured personal loans in the home credit market; branch unsecured consumer loans; and guaranteed loans. It currently has negative earnings.

More recent Non-Standard Finance plc (LON:NSF) news were published by: Reuters.com which released: “Metal recyclers prepare for electric car revolution – Reuters” on November 17, 2017. Also Prweb.com published the news titled: “World’s Largest Recovery App, Sober Grid, Can Now Predict Relapses with Artificial Intelligence – PR Web” on February 19, 2018. Prnewswire.com‘s news article titled: “Indivior Announces Regulatory Submission to Australia’s Therapeutic Goods Administration (TGA) for SUBLOCADEâ„¢ (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence – PR Newswire” with publication date: May 25, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.